Accelerate Diagnostics (NASDAQ:AXDX) Announces Earnings Results, Beats Expectations By $0.13 EPS

Accelerate Diagnostics (NASDAQ:AXDX) announced its earnings results on Thursday. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.13, Zacks reports. The firm had revenue of $2.82 million during the quarter, compared to analyst estimates of $3.00 million.

Accelerate Diagnostics Stock Performance

Shares of Accelerate Diagnostics stock traded down $0.07 during trading on Friday, reaching $1.06. 156,774 shares of the company’s stock were exchanged, compared to its average volume of 59,715. Accelerate Diagnostics has a 1-year low of $0.73 and a 1-year high of $2.09. The company has a market cap of $26.55 million, a P/E ratio of -0.37 and a beta of 0.55. The firm’s 50-day moving average price is $1.16 and its 200 day moving average price is $1.45.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. StockNews.com assumed coverage on Accelerate Diagnostics in a research report on Monday, March 17th. They issued a “hold” rating on the stock. BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a research report on Wednesday, December 11th.

Accelerate Diagnostics Company Profile

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.